Viral Vectors and Plasmid DNA Manufacturing Market Report 2025 (Global Edition)

Global Viral Vectors and Plasmid DNA Manufacturing Market Report 2025 Market Size Split by Type (Lentivirus, Adenovirus, Adeno-associated Virus (AAV), Plasmid DNA, Others), by Application (Gene Therap...

Viral Vectors and Plasmid DNA Manufacturing Market Report Description

We have various report editions of Viral Vectors and Plasmid DNA Manufacturing Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Viral Vectors and Plasmid DNA Manufacturing Market Insights Video

Competitive Landscape of the Viral Vectors and Plasmid DNA Manufacturing Market

The competitive landscape of the Viral Vectors and Plasmid DNA Manufacturing market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established viral vectors and plasmid DNA manufacturers, specialized Gene Therapy companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

May 2024: Charles River Laboratories launched the Modular and Fast-track viral vector tech transfer frameworks to expedite gene therapy development rooted in the company's extensive CDMO legacy. This aims to ensure seamless process transfer to its Maryland-based viral vector Center of Excellence in as little as nine months. (Source: https://ir.criver.com/news-releases/news-release-details/charles-river-launches-viral-vector-tech-transfer-program) May 2023: AGC Biologics introduced BravoAAV and ProntoLVV viral vector technologies for quick, cost-effective, and sustainable GMP production and release. The company's proprietary processes and capsid-specific methods that deliver GMP products in only 9 months. (Source: https://www.agcbio.com/news/agc-biologics-launches-bravo-aav-and-pronto-lvv-viral-vector-platforms)

Top Companies Market Share in Viral Vectors and Plasmid DNA Manufacturing Industry: (In no particular order of Rank)

• Merck KGaA (Germany)
• Lonza (Switzerland)
• FUJIFILM Diosynth Biotechnologies (USA)
• Thermo Fisher Scientific (USA)
• Cobra Biologics (UK)
• Catalent Inc. (USA)
• Wuxi Biologics (China)
• Takara Bio Inc. (Japan)
• Waisman Biomanufacturing (USA)
• Genezen Laboratories (USA)
• Batavia Biosciences (Netherlands)
• Miltenyi Biotec GmbH (Germany)
• SIRION Biotech GmbH (Germany)
• Virovek Incorporation (USA)
• BioNTech IMFS GmbH (Germany)
• Audentes Therapeutics (USA)
• BioMarin Pharmaceutical (USA)
• RegenxBio
• Inc. (USA)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Viral Vectors and Plasmid DNA Manufacturing Market

Which Region Dominates the Viral Vectors and Plasmid DNA Manufacturing Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40.0% of the global revenue because of the area's increasing demand for gene therapies, stringent environmental regulations, and technological advances for the effective utilization of Viral Vectors and Plasmid DNA Manufacturing in various diseases increasing the Viral Vectors and Plasmid DNA Manufacturing market in North America.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Viral Vectors and Plasmid DNA Manufacturing market due to several compelling reasons. ?The viral vectors and plasmid DNA manufacturing marketplace in the Asia Pacific is developing owing to the increasing population, rapid economic growth, and increased incidence of cancer patients led to the demand for viral vectors and plasmid DNA manufacturing applications for targeted cancer treatments and innovative gene therapies driving the market growth in the Asia Pacific.

The current report Scope analyzes Viral Vectors and Plasmid DNA Manufacturing Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Viral Vectors and Plasmid DNA Manufacturing Market

According to Cognitive Market Research, the global Viral Vectors and Plasmid DNA Manufacturing market size was estimated at USD 936.5 Million, out of which North America held the major market of more than 40.0% of the global revenue with a market size of USD 374.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Viral Vectors and Plasmid DNA Manufacturing market with a market size of USD 295.56 million in 2024 and is projected to grow at a CAGR of 9.6% during the forecast period. The demand is amplified by the high adoption rate of new therapies and investments by key players in the U.S
• The Canada Viral Vectors and Plasmid DNA Manufacturing market had a market share of USD 44.95 million in 2024 and is projected to grow at a CAGR of 10.6% during the forecast period. Canada's Favorable regulatory for cancer diseases increased the market of viral vectors and plasmid DNA manufacturing.
• The Mexico Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 34.09 million in 2024.

Europe Viral Vectors and Plasmid DNA Manufacturing Market

According to Cognitive Market Research, the global Viral Vectors and Plasmid DNA Manufacturing market size was estimated at USD 936.5 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 2685.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.

• The United Kingdom Viral Vectors and Plasmid DNA Manufacturing market had a market share of USD 47.20 million in 2024 and is projected to grow at a CAGR of 10.9% during the forecast period. Increasing research investment for advancements in technology to improve the utilization of Viral Vectors and Plasmid DNA Manufacturing drive sales in the UK
• The France Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 25.85 million in 2024.
• According to Cognitive Market Research, the German viral Vectors and Plasmid DNA Manufacturing market size was valued at USD 55.63 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. In Germany, Viral Vectors and Plasmid DNA Manufacturing sales surged due to the increasing demand for gene therapies.
• The Italy Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 24.16 million in 2024.
• The Russia Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 43.55 million in 2024.
• The Spain Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 9.2% during the forecast period with a market size of USD 23.04 million in 2024
• The Luxembourg Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 8.71 million in 2024.
• The Portugal Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 9.9% during the forecast period, with a market size of USD 5.90 million in 2024.
• The Greece Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.4% during the forecast period, with a market size of USD 3.37 million in 2024.
• The Rest of Europe's Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 43.55 million in 2024.

Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market

According to Cognitive Market Research, the global Viral Vectors and Plasmid DNA Manufacturing market size was estimated at USD 936.5 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 215.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.

• According to Cognitive Market Research, the China Viral Vectors and Plasmid DNA Manufacturing market size was valued at USD 96.93 million in 2024 and is projected to grow at a CAGR of 13.1% during the forecast period. Viral Vectors and Plasmid DNA Manufacturing sales surged in China due to the increasing aging population led to the demand for gene therapies.
• The Japan Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 12.1% during the forecast period, with a market size of USD 29.72 million in 2024.
• The India Viral Vectors and Plasmid DNA Manufacturing market had a market share of USD 25.85 million in 2024 and is projected to grow at a CAGR of 15.4% during the forecast period. India's government initiatives towards research institutes for vaccination and gene therapies drive the demand of the market.
• The South Korean viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 21.54 million in 2024.
• The Australian viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD 11.20 million in 2024.
• The South East Asia Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 14.6% during the forecast period, with a market size of USD 14.86 million in 2024.
• The Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 15.29 million in 2024.

South America Viral Vectors and Plasmid DNA Manufacturing Market

According to Cognitive Market Research, the global Viral Vectors and Plasmid DNA Manufacturing market size was estimated at USD 936.5 Million out of which the Latin America market of more than 5% of the global revenue with a market size of USD 46.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.0% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Viral Vectors and Plasmid DNA Manufacturing market size was valued at USD 20.04 million in 2024 and is projected to grow at a CAGR of 11.6% during the forecast period. Viral Vectors and Plasmid DNA Manufacturing sales flourish in Brazil due to the favorable legal environment policies contributing to its attractiveness to market players.
• Argentina's Viral Vectors and Plasmid DNA Manufacturing market had a market share of USD 7.87 million in 2024 and is projected to grow at a CAGR of 11.9% during the forecast period. The increasing demand for generic medicine and new therapies increases in Argentina drives the sales of Viral Vectors and Plasmid DNA Manufacturing.
• Colombia's Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.8% during the forecast period with a market size of USD 4.17 million in 2024.
• Peru's Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 11.4% during the forecast period with a market size of USD 3.84 million in 2024.
• Chile's Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 11.3% during the forecast period with a market size of USD 3.37 million in 2024.
• The Rest of Latin America's Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.1% during the forecast period, with a market size of USD 7.54 million in 2024.

Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market

According to Cognitive Market Research, the global Viral Vectors and Plasmid DNA Manufacturing market size was estimated at USD 936.5 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 18.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.3% from 2024 to 2031.

• The GCC Countries Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 12.1% during the forecast period with a market size of USD 8.02 million in 2024. Viral Vectors and Plasmid DNA Manufacturing sales flourish due to supportive government policies for healthcare.
• The Egypt Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 11.6% during the forecast period, with a market size of USD 1.97 million in 2024.
• The South Africa Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD 2.96 million in 2024. Viral Vectors and Plasmid DNA Manufacturing sales flourish in South Africa due to the need for personalized medicine and alternative therapies.
• The Turkey Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.8% during the forecast period, with a market size of USD 1.61 million in 2024.
• The Nigeria Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.4% during the forecast period, with a market size of USD 1.97 million in 2024.
• The Rest of the MEA Viral Vectors and Plasmid DNA Manufacturing market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 2.21 million in 2024.

Viral Vectors and Plasmid DNA Manufacturing Market Analysis

Viral Vectors and Plasmid DNA Manufacturing Market Type Segment Analysis

According to Cognitive Market Research, adeno-associated virus (AAV) stands out as the dominating category. AAV vectors are desirable for gene therapy because they are not pathogenic and can lead to the expression of genes for a long time without becoming part of host genetic material; thereby, lowering insertion mutagenesis danger. The AAV's ability to target multiple tissues effectively qualifies them as a good option for treating multiple genetic disorders. Moreover, their widespread adoption in both clinical and preclinical studies drives their segment in the market.

Plasmid DNA emerges as the fastest-growing category in the Viral Vectors and Plasmid DNA Manufacturing market. Due to its vital use in the production of viral vectors and its use as a direct therapeutic agent in DNA-based vaccines and gene therapies, the Plasmid DNA segment has the highest CAGR. The importance of plasmid DNA demand has been increase for quick vaccine creation during the COVID-19 pandemic. Moreover, advancements in plasmid DNA manufacturing technologies have improved scalability and cost-efficiency, making it more accessible for various applications. Therefore, the desire for cancer immunotherapies together with DNA-based vaccines for infectious disease treatment advocate for further development in this market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Viral Vectors and Plasmid DNA Manufacturing Industry. Request a Free Sample PDF!

Viral Vectors and Plasmid DNA Manufacturing Market Application Segment Analysis

According to Cognitive Market Research, the dominating category is gene therapy. his dominance is fueled by the rising incidence of chronic illnesses and genetic problems, which need innovative treatment approaches. Furthermore, gene therapy used to treat various conditions like hemophilia, muscular dystrophy, and certain cancers makes it essential in this market dominant. Moreover, the growing number of gene therapy candidates in clinical trials and the recent approvals of gene therapy products have propelled this segment to hold the highest market share.

The fastest-growing category in the Viral Vectors and Plasmid DNA Manufacturing market is Vaccinology. The pandemic of COVID-19 has displayed that there is a crucial requirement for efficient immunizations against new infectious ailments significantly leading to the demand for viral vectors and plasmid DNA in vaccine production. Moreover, expanding applications in both human and veterinary medicine, innovation in vaccines for various diseases, and increasing government immunization programs all are driving the market in the future.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Viral Vectors and Plasmid DNA Manufacturing Disease Segment Analysis

Disease Segment Analysis

According to Cognitive Market Research, the dominating category is Genetic Disorders mainly due to the increasing prevalence of genetic conditions. Individualized treatments for genetic ailments often need to be administered accurately using effective carriers of the therapeutic genes. Hence, viral vectors together with plasmid DNA have become indispensable in driving the market in gene therapies. Due to the effectiveness of therapies for diseases like hemophilia and spinal muscular atrophy have significant investment and development, securing its dominant position in the market..

The fastest-growing category in the Viral Vectors and Plasmid DNA Manufacturing market is Cancer. This is facilitated by the increasing clinical trial and approval for viral vector cancer prevalence treatment. Advancement and acceptance of new treatments for cancer treatment, like oncolytic viral therapies and CAR-T cell therapies, necessitate a lot of viral vectors and plasmid DNA. Furthermore, an increased amount of investment in treating cancer diseases boost the demand for this segment in the future.

• Genetic Disorders
• Cancer
• Infectious Diseases
• Others

Viral Vectors and Plasmid DNA Manufacturing End Users Segment Analysis

End Users Segment Analysis

According to Cognitive Market Research, the dominating category is Biotech Companies. Innovation in advanced biotechnologies such as gene treatment and vaccination is mostly driven by biotech companies. They make significant investments in the development and marketing of novel treatments, and they use plasmid DNA and viral vectors for product development. Their dominant position in the market is maintained by the biotech industry's ongoing growth, significant funding, and strategic alliances, securing its dominant position in the market.

The fastest-growing category in the Viral Vectors and Plasmid DNA Manufacturing market is Research Institutes. The market is mainly driven by growing government and academic research projects aimed at comprehending genetic illnesses, establishing new vaccination platforms, and creating innovative gene therapies are the main drivers of this increase. Moreover, research institutes frequently provide clinical testing for innovative technologies that biotech businesses subsequently drive the research institutes' market.

• Biotech Companies
• Research Institutes

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion